NCT03919617View on ClinicalTrials.gov

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

May 31, 2022

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

REMD-477

4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.

Trial Locations (1)

92037

UC San Diego Altman Clinical & Translational Research Institute, La Jolla

All Listed Sponsors
collaborator

REMD Biotherapeutics, Inc.

INDUSTRY

lead

University of California, San Diego

OTHER

NCT03919617 - Metabolic Pathways of GRA in Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter